We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particul... Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Show more
Ask ADVFN Intelligence (AI)
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates...
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...
CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...
LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from...
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
PonkenPlonken
6 months ago
TrendTrade2016
6 months ago
TrendTrade2016
6 months ago
TrendTrade2016
6 months ago
glenn1919
7 months ago
Renee
8 months ago
stock1ace1
8 months ago
Triple nickle
8 months ago
Awl416
8 months ago
Awl416
8 months ago
Tom turtles
8 months ago
Awl416
8 months ago
Awl416
10 months ago
81vette
10 months ago
Monroe1
10 months ago
Monksdream
11 months ago
Monksdream
1 year ago
Monksdream
1 year ago
Monksdream
1 year ago
Monksdream
1 year ago
81vette
2 years ago
81vette
2 years ago
81vette
2 years ago
81vette
2 years ago
81vette
2 years ago
81vette
2 years ago
bandit007
3 years ago
bandit007
3 years ago
bandit007
3 years ago
bandit007
3 years ago
TheFinalCD
3 years ago
bandit007
3 years ago
bandit007
3 years ago
bandit007
3 years ago
bandit007
3 years ago
Deano361
3 years ago
Deano361
3 years ago
bandit007
3 years ago
bandit007
3 years ago
crudeoil24
3 years ago
TheFinalCD
3 years ago
Awl416
3 years ago
TheFinalCD
3 years ago
crudeoil24
3 years ago
crudeoil24
3 years ago
crudeoil24
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
